Pharmaceutical companies keen to improve transparency, analysts say

China's crackdown on medical bribery will prompt foreign drugmakers to change their practices in the country, analysts said.

"We are already seeing these pharmaceutical companies' willingness to improve transparency and adjust their practices, and I believe it will happen," said Keith Bowman, an equity analyst at Hargreaves Lansdown Stockbrokers in London.